Table 1. Clinical Data of the Patients... | American Society of Hematology

Table 1.

Clinical Data of the Patients Included in This Study

	Age/Sex	Disease	Type of BMT	Plasma Exchange	Cyclosporin Treatment	Result of Treatment	Survival Time (mo)	LDH (U/L)	Creatinin (μmol/L)	Hb (mmol/L)	Platelets (×10⁹/L)	CellularFibronectin (ng/mL)	vWF:Ag (%)	vWF:RiCof (%)
Primary TTP Patients
1	43/F			Yes		Good	22	1,311	62	5, 1	16	2,943	81	53
2	25/F			Yes		Good	39	1,482	76	6, 4	5	2,221	88	71
3	35/F			Yes		Good	44	2,086	188	6, 1	44	2,331	129	67
4	29/F			Yes		Good	4	4,901	75	2, 9	11	3,219	196	132
5	29/F			Yes		Good	4	1,777	86	5, 2	30	1,988	82	47
BMT-Associated TTP Patients
6	57/M	MM	Autologous		Started	Good	50	658	121	4, 1	64	5,153	261	137
7	40/M	Hodgkin’s	Autologous		Started	Good	59	768	155	5, 0	49	2,932	181	104
8	52/F	NHL	Autologous	Yes^*	Started	On dialysis	72	1,276	152	4, 6	24	2,244	263	185
9	16/M	NHL	Autologous	Yes^*	Started	Good	56	999	201	4, 6	44	1,825	148	90
10	37/F	ALL	Allogeneic		Stopped	Good^†	2	1,016	86	5, 9	17	2,212	320	238
11	49/F	MDS	Allogeneic	Yes^*		^†	1	1,959	209	5, 3	43	5,275	485	125
12	35/M	ALL	Allogeneic		Stopped	Good^†	17	3,570	345	5, 5	19	3,444	470	243
13	53/M	AA	Allogeneic		Stopped	Good^†	1	4,300	210	5, 0	5	3,010	620	300

	Age/Sex	Disease	Type of BMT	Plasma Exchange	Cyclosporin Treatment	Result of Treatment	Survival Time (mo)	LDH (U/L)	Creatinin (μmol/L)	Hb (mmol/L)	Platelets (×10⁹/L)	CellularFibronectin (ng/mL)	vWF:Ag (%)	vWF:RiCof (%)
Primary TTP Patients
1	43/F			Yes		Good	22	1,311	62	5, 1	16	2,943	81	53
2	25/F			Yes		Good	39	1,482	76	6, 4	5	2,221	88	71
3	35/F			Yes		Good	44	2,086	188	6, 1	44	2,331	129	67
4	29/F			Yes		Good	4	4,901	75	2, 9	11	3,219	196	132
5	29/F			Yes		Good	4	1,777	86	5, 2	30	1,988	82	47
BMT-Associated TTP Patients
6	57/M	MM	Autologous		Started	Good	50	658	121	4, 1	64	5,153	261	137
7	40/M	Hodgkin’s	Autologous		Started	Good	59	768	155	5, 0	49	2,932	181	104
8	52/F	NHL	Autologous	Yes^*	Started	On dialysis	72	1,276	152	4, 6	24	2,244	263	185
9	16/M	NHL	Autologous	Yes^*	Started	Good	56	999	201	4, 6	44	1,825	148	90
10	37/F	ALL	Allogeneic		Stopped	Good^†	2	1,016	86	5, 9	17	2,212	320	238
11	49/F	MDS	Allogeneic	Yes^*		^†	1	1,959	209	5, 3	43	5,275	485	125
12	35/M	ALL	Allogeneic		Stopped	Good^†	17	3,570	345	5, 5	19	3,444	470	243
13	53/M	AA	Allogeneic		Stopped	Good^†	1	4,300	210	5, 0	5	3,010	620	300

Abbreviations: AA, aplastic anemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; ALL, acute lymphoblastic leukemia.

No improvement after plasma exchange.

Developed lethal complications unrelated to TTP.